Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,083 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biomarkers for Alzheimer's disease therapeutic trials.
Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B; Oxford Task Force Group. Hampel H, et al. Among authors: blennow k. Prog Neurobiol. 2011 Dec;95(4):579-93. doi: 10.1016/j.pneurobio.2010.11.005. Epub 2010 Dec 2. Prog Neurobiol. 2011. PMID: 21130138 Review.
Genetically predicted telomere length and Alzheimer's disease endophenotypes: a Mendelian randomization study.
Rodríguez-Fernández B, Vilor-Tejedor N, Arenaza-Urquijo EM, Sánchez-Benavides G, Suárez-Calvet M, Operto G, Minguillón C, Fauria K, Kollmorgen G, Suridjan I, de Moura MC, Piñeyro D, Esteller M, Blennow K, Zetterberg H, De Vivo I, Molinuevo JL, Navarro A, Gispert JD, Sala-Vila A, Crous-Bou M; ALFA study. Rodríguez-Fernández B, et al. Among authors: blennow k. Alzheimers Res Ther. 2022 Nov 7;14(1):167. doi: 10.1186/s13195-022-01101-9. Alzheimers Res Ther. 2022. PMID: 36345036 Free PMC article.
Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients.
Smith R, Cullen NC, Pichet Binette A, Leuzy A, Blennow K, Zetterberg H, Klein G, Borroni E, Ossenkoppele R, Janelidze S, Palmqvist S, Mattsson-Carlgren N, Stomrud E, Hansson O; Alzheimer's Disease Neuroimaging Initiative. Smith R, et al. Among authors: blennow k. Alzheimers Dement. 2023 Jun;19(6):2497-2507. doi: 10.1002/alz.12875. Epub 2022 Dec 14. Alzheimers Dement. 2023. PMID: 36516028
CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals.
Simrén J, Brum WS, Ashton NJ, Benedet AL, Karikari TK, Kvartsberg H, Sjons E, Lussier FZ, Chamoun M, Stevenson J, Hopewell R, Pallen V, Ye K, Pascoal TA, Zetterberg H, Rosa-Neto P, Blennow K. Simrén J, et al. Among authors: blennow k. Alzheimers Res Ther. 2022 Dec 22;14(1):192. doi: 10.1186/s13195-022-01142-0. Alzheimers Res Ther. 2022. PMID: 36544221 Free PMC article.
Blood-brain barrier opening of the default mode network in Alzheimer's disease with magnetic resonance-guided focused ultrasound.
Meng Y, Goubran M, Rabin JS, McSweeney M, Ottoy J, Pople CB, Huang Y, Storace A, Ozzoude M, Bethune A, Lam B, Swardfager W, Heyn C, Abrahao A, Davidson B, Hamani C, Aubert I, Zetterberg H, Ashton NJ, Karikari TK, Blennow K, Black SE, Hynynen K, Lipsman N. Meng Y, et al. Among authors: blennow k. Brain. 2023 Mar 1;146(3):865-872. doi: 10.1093/brain/awac459. Brain. 2023. PMID: 36694943 Free PMC article.
Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit.
Johnson SC, Suárez-Calvet M, Suridjan I, Minguillón C, Gispert JD, Jonaitis E, Michna A, Carboni M, Bittner T, Rabe C, Kollmorgen G, Zetterberg H, Blennow K. Johnson SC, et al. Among authors: blennow k. Alzheimers Res Ther. 2023 Jan 28;15(1):25. doi: 10.1186/s13195-023-01168-y. Alzheimers Res Ther. 2023. PMID: 36709293 Free PMC article.
Dementia prevention in memory clinics: recommendations from the European task force for brain health services.
Frisoni GB, Altomare D, Ribaldi F, Villain N, Brayne C, Mukadam N, Abramowicz M, Barkhof F, Berthier M, Bieler-Aeschlimann M, Blennow K, Brioschi Guevara A, Carrera E, Chételat G, Csajka C, Demonet JF, Dodich A, Garibotto V, Georges J, Hurst S, Jessen F, Kivipelto M, Llewellyn DJ, McWhirter L, Milne R, Minguillón C, Miniussi C, Molinuevo JL, Nilsson PM, Noyce A, Ranson JM, Grau-Rivera O, Schott JM, Solomon A, Stephen R, van der Flier W, van Duijn C, Vellas B, Visser LNC, Cummings JL, Scheltens P, Ritchie C, Dubois B. Frisoni GB, et al. Among authors: blennow k. Lancet Reg Health Eur. 2023 Jan 31;26:100576. doi: 10.1016/j.lanepe.2022.100576. eCollection 2023 Mar. Lancet Reg Health Eur. 2023. PMID: 36895446 Free PMC article. Review.
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Bateman RJ, et al. Among authors: blennow k. N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430. N Engl J Med. 2023. PMID: 37966285 Clinical Trial.
2,083 results